Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

play

Maribeth Capuno

DNP, RN, ANP-BC

Maribeth Capuno obtained her Master of Science in Nursing from Emory University in 1996. She was then certified as an Adult Nurse Practitioner. She worked as a Nurse Practitioner in Cardiology for over 20 years, specializing in Heart Failure. In 2019, she advanced her education by obtaining her Doctor of Nursing Practice from the University of Virginia. In 2021, she relocated to Richmond Virginia and took a position in the Hepatology department at the Richmond Veteran's Affairs Medical Center. In this position, her focus has been on patients with MASLD/MASH throughout the spectrum of their disease. She works with her patients to develop an individualized plan of care to assist them in controlling their metabolic conditions which are contributing to their liver disease. She also is a Sub-Investigator on multiple MASLD/MASH clinical trials.

play

Summer Collier

MSN, FNP-BC

Summer Collier is a nurse practitioner with advanced expertise in hepatology and a strong commitment to evidence-based, multidisciplinary care. At UC San Diego Health, she provides comprehensive management for patients with chronic liver disease, including viral hepatitis, autoimmune hepatitis, alcohol-associated liver disease, and metabolic dysfunction–associated steatotic liver disease (MASLD). Collier is actively engaged in clinical research and has participated in multidisciplinary studies on liver fibrosis, steatosis, and treatment protocols for hepatitis C and alcohol use disorder. Her scholarly work focuses on improving transitions of care for patients with cirrhosis and expanding access to pharmacologic treatments for patients with alcohol use disorder. A recognized leader in the field, Collier has presented at national conferences including The Liver Meeting (AASLD), Digestive Disease Week (DDW), and GHAPP, speaking on topics such as cirrhosis care, hepatology red flags, and advanced practice provider leadership. She previously served as Chair of the Advanced Practice Council at UC San Diego Health, driving initiatives that elevated APP visibility and impact within the organization. Before joining UC San Diego Health, she was a family nurse practitioner and HIV specialist with Family Health Centers of San Diego. She also has prior experience as a registered nurse. Collier completed a Master of Science in Nursing degree from University of San Diego and will complete the Doctor of Nursing Practice degree from University of California, Los Angeles in June 2025. She is certified by the American Nurses Credentialing Center.

play

Jessica Crimaldi

MSN, NP-C, CMSRN

Jessica Crimaldi, MSN, APRN,CNP, CMSRN was born and raised in the greater Cleveland area. She attended Cleveland State University for her BSN; during her time at CSU she had the opportunity to work at The Cleveland Clinic Foundation in a 3-year internship entitled the "Nursing Experiential Program." In this role she had the opportunity to learn many of the roles on a typical nursing unit while working 1 year as a Unit Secretary, 1 year as a Nurse Assistant and 1 year as a Nurse Intern. She started her nursing career on an inpatient Internal Medicine and Telemetry Teaching Unit where she worked as an RN while completing her MSN at the University of Akron. Since graduation in 2015 she has worked as a Nurse Practitioner in the Department of Gastroenterology, Hepatology and Nutrition seeing inpatients with gastrointestinal and liver disorders at The Cleveland Clinic Foundation. In addition, to her clinical role, she is also the Manager for over 50 Gastroenterology, Hepatology and Nutrition APPs. She is the Co-Director for the nation's first Inflammatory Bowel Disease APP Fellowship which is in its third year. She has presented nationally and published in The Journal for Nurse Practitioners (JNP). She is Faculty for Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) National Organization and Milestone APP. When she is not busy with work Jessica is a wife, parent to 2 young children and dog mom. She is a foster parent and passionate about improving the foster care system. She enjoys being outdoors, hiking and spending time with family and friends.

play

Jeremy Davis

ACNP-BC

Jeremy Davis ACNP is a board-certified acute care nurse practitioner who has been practicing in the focus of hepatology at GastroIntestinal Specialists A.M.C. since 2012. Jeremy’s areas of interest include MASLD, MASH, Hepatitis B, Hepatitis C, cholestatic liver disease, and autoimmune liver disease. Jeremy has been an active faculty ambassador of Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) since 2019 and is a lecturer at both regional and national conferences. Jeremy is also an Associate member of the American Association for the Study of Liver Diseases (AASLD) since 2014. Jeremy received his Bachelor of Science degree and Master of Science Degree in Nursing from Northwestern State University in Natchitoches, Louisiana. Jeremy’s hobbies include spending time with his family, cooking and traveling.

play

Sarah Dawkins

FNP-C, MSN, RN

Sarah Dawkins, FNP-C, is a family nurse practitioner specializing in general and transplant hepatology at Duke University Medical Center, where she has practiced since 2017. She holds a BS in Biology and a BA in Romance Languages from the University of North Carolina at Chapel Hill. Sarah completed the Accelerated Bachelor of Science in Nursing (ABSN) program at Duke University and worked in the Neuroscience ICU at Duke while earning her Master of Science in Nursing (MSN). She became a certified family nurse practitioner in 2015 and initially worked in a private gastroenterology practice before joining Duke Gastroenterology. Her clinical interests include autoimmune liver disease, transplant hepatology and metabolic dysfunction-associated steatotic liver disease (MASLD). Sarah currently serves as the Advanced Practice Provider (APP) Team Lead for the GI Division at Duke. Outside of work, she enjoys traveling, trying new restaurants, attending fitness classes, cheering on the UNC Tar Heels, and spending time with her three young children and their orange cat, Zeus.

play

Anthony Derencius

MPAS, PA-C

Anthony Derencius, PA-C is a former U.S. Army medic and a 2010 honor graduate of the military’s Interservice Physician Assistant Program. During his 11 years in the Army, he provided care to patients and soldiers around the world, including deployments to Afghanistan and Iraq. After leaving the Army, PA-C Derencius focused his clinical career in the gastroenterology and hepatology field. He has worked in private practice GI in Hawaii and in both general and transplant hepatology in San Antonio, gaining extensive outpatient and inpatient experience. In 2024, he joined Pinnacle Clinical Research, bringing a wealth of clinical expertise to his role as an investigator in many clinical trials for MASLD and other liver diseases. In 2018, he completed a one-year American Association for the Study of Liver Disease (AASLD) Foundation NP/PA Clinical Hepatology Fellowship. He is also an active member of several medical societies, including the American College of Gastroenterology (ACG) and the AASLD.

Stacie Egan

DNP, FNP-C

Stacie Egan, DNP, FNP-C, is a Family Nurse Practitioner specializing in gastroenterology, practicing with the Ogden Clinic in Utah. Born and raised in the Ogden area, she completed her Bachelor of Science in Nursing at Weber State University, graduating summa cum laude. She went on to earn her Master of Science in Nursing from the University of Cincinnati, and most recently her Doctor of Nursing Practice degree, which she obtained in 2022. Stacie joined Ogden Clinic in 2017 and works primarily through the Layton Specialty location, where she focuses on digestive health, disease prevention, and helping patients improve quality of life through clinical care and education. Her passion for gastroenterology stems from her strong belief in the impact of preventative health and the importance of gut health in overall wellness. Beyond her clinical work, Stacie values a patient-centered approach—listening to patients, addressing their concerns, and applying her knowledge to support them in achieving better health outcomes. She resides locally, is married, and in her free time enjoys Utah’s outdoor lifestyle, including trail running, enjoying natural areas like Snowbasin, and participating in the Ogden Marathon.

play

Melissa Franco

PA-C, MMS

Melissa Franco is a Physician Associate at the University of Miami- specializing in the management of patients with liver diseases, ranging from acute hepatitis to complex chronic conditions such as cirrhosis and liver cancer. With a strong focus on MASH, autoimmune hepatitis, PBC, viral hepatitides, and cirrhosis- Melissa is dedicated to delivering compassionate, comprehensive care tailored to each patient's unique needs. She is deeply committed to patient education, and strives to empower individuals to take an active role in their health journey, fostering collaboration, and confidence at every stage of care.

play

Jennifer Geremia

MPAS, PA-C

Jennifer Geremia, MPAS, PA-C, is a practicing Physician Assistant in outpatient Gastroenterology at Brigham and Women's Hospital in Boston. With GI experience for 15 years including community GI care in RI and currently tertiary care. In addition to clinical practice she enjoys educating both her peers and future PAs. Jennifer currently teaches at UNE, MCPHS and MGH PA programs. She is also on the Education committee and faculty for GHAPP and is actively working on the AGA APP task force as well as an APP contributor to ASGE .

play

HoChong Gilles

DNP, FNP-BC, AF-AASLD

HoChong Gilles earned dual Bachelor of Science degrees in Biology and Nursing, followed by a Master of Science in Nursing from Virginia Commonwealth University. In 2018, she completed her Doctorate in Nursing Practice at the University of Virginia. With over 25 years of experience as a Nurse Practitioner specializing in hepatology, Dr. Gilles currently serves as the Clinical Program Director for the Gastroenterology and Hepatology Division and Assistant Director of GI Research in Richmond, Virginia. Her clinical and research interests encompass metabolic dysfunction associated steatotic liver disease (MASLD/MASH), portal hypertension, liver transplantation, and hepatocellular carcinoma. An active member of the liver disease community, she is proud to hold the designation of Associate Fellow with the American Association for the Study of Liver Disease (AASLD).

play

Elizabeth Goacher

PA-C

Elizabeth Goacher is a Physician Assistant with Duke University Medical Center, Department of Medicine, Gastroenterology Division, Duke Liver Center, April 2001 to the present. Her pronouns are she/her. She is currently engaged in full time clinical practice in Hepatology. Her clinical work encompasses the full spectrum of liver disease patient population, from early stage disease to end of life, with a particular interest in portal hypertension. She served as Team Lead for the Duke Division of Gastroenterology Advanced Practice group of 25 Advanced Practice Providers 2014-2023. She is also lecturer and preceptor at Duke University School of Medicine Physician Assistant Program. Elizabeth graduated from the Duke University School of Medicine Physician Assistant Program in 1998 after earning her Bachelor of Arts from University of North Carolina at Chapel Hill in 1991. She is past Chair of the Hepatology Associates Committee of the American Association for the Study of Liver Diseases and was a member of the inaugural class of Associate Fellows of AASLD in 2020. When she is not at work, she maintains a health boundary from technology (aka EPIC) and spends as much time outdoors as possible. When asked to design and implement her dream job, she would own and operate a cocktail and tapas venue while instructing fitness classes on a large piece of lakeside property in North Carolina alongside her canine rescue, foster and retraining agency.

play

Ellie Gonyeau

NP

Ellie Gonyeau is a board-certified Nurse Practitioner specializing in gastroenterology at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She earned her Nurse Practitioner degree from Simmons University and has been practicing since 2020. Ellie is affiliated with Cape Cod Hospital and Beth Israel Deaconess Medical Center, providing comprehensive care to patients with various gastrointestinal conditions. She is committed to delivering patient-centered care and building long-term, trusting relationships with her patients.

Tina Gregg

NP-C

Tina Marie Gregg, NP-C, is a board-certified nurse practitioner specializing in gastroenterology with a particular focus on liver disease. She serves as The Liver Clinic Specialist at GI Associates & Endoscopy Center in Flowood, Mississippi, where she provides comprehensive care for patients with conditions such as cirrhosis, fatty liver disease, hepatitis, and other chronic liver disorders. Tina earned her Bachelor of Science in Nursing from Mississippi College and has been certified by the American Academy of Nurse Practitioners since 2007. At GI Associates, she is actively involved in both clinic visits and procedural care, coordinating diagnostic evaluations, treatment plans, and long-term disease management. Known for her compassionate and thorough approach, Tina is dedicated to helping patients understand their conditions and treatment options while ensuring close follow-up and ongoing support.

play

Janet Gripshover

DNP, MBA

Janet Gripshover, DNP, MBA, AF-AASLD, is a highly experienced Family Nurse Practitioner and Nurse Manager for Cedars-Sinai’s Liver Transplant Program in Los Angeles. With over 15 years of clinical and leadership expertise in hepatology, Dr. Gripshover is recognized for her commitment to advancing the role of Advanced Practice Providers (APPs) in liver care. She has led numerous initiatives to foster APP education and collaboration, including founding the APP HCV Consortium in Baltimore, MD, and creating the GI APP Grand Rounds series at Geisinger Wyoming Valley in Wilkes-Barre, PA. In addition to speaking at national conferences, Dr. Gripshover has developed and delivered a wide range of educational and professional development seminars for non-physician providers across the country. An advocate for patient-centered innovation, she also founded and moderated the first hospital-sponsored Facebook support group for liver transplant recipients — a project that earned her the New Media Award for Healthcare from the Baltimore Business Journal and national recognition. Dr. Gripshover is an active member of the American Association for the Study of Liver Diseases (AASLD), where she has served on the Hepatology Associates Committee and the Women’s Initiatives Committee, helping launch the AASLD Women’s Leadership Program. She currently serves as Vice Chair of AASLD’s Hepatology Associates Special Interest Group and is also a member of the Hepatology Associates Committee for the American College of Gastroenterology (ACG).

play

Christina Hanson

FNP-C

Christina Hanson is a nurse practitioner in Gastroenterology and Hepatology at South Denver GI, with nearly 20 years of clinical practice. She is a course director and board of trustee for GHAPP. An active researcher with extensive leadership and teaching experience, she is a champion of evidence-based practice, data-driven care delivery, interdisciplinary collaboration, and quality patient care. Christina is committed to amplifying professional development, growth, and contributions of advanced practice.

play

Patrick Horne

ARNP

Patrick M. Horne, MSN, APRN-BC, FNP, AF-AASLD is the Assistant Director of Clinical Hepatology Research and Clinical Programs Coordinator at the University of Florida’s Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition. He holds bachelor's and master's degrees from the University of Florida College of Nursing. His research focuses on hepatology clinical trials, including viral hepatitis, MASH, autoimmune hepatitis, cholestatic liver disease, and HCC. He has published extensively in clinical hepatology and has presented at major conferences such as AASLD, AGA NP/PA, and GHAPP.

play

Lavinia Iordache

PA-C

Lavinia Iordache earned her Masters of Clinical Medical Science from Barry University in Miami and she has been practicing as a Physician Associate in the field of Hepatology for the past 10 years. She completed a one year AASLD fellowship under the guidance of her supervising physicians and she continues to provide care to a complex patient population in an academic environment. She previously attended Medical School in her home country of Romania and graduated Magna Cum Laude from Florida International University with a Bachelor Degree in Biochemistry. She holds a NCCPA certification and is a proud member of several professional associations as well as animal welfare organizations. Her dedication to helping people with liver disease extends to both inpatient and outpatient settings and she has been expanding her clinical practice to include Internal Medicine as well as General Gastroenterology. She values a holistic and patient-centered approach to care and is a big advocate for patient education, always striving to connect with her patients to promote understanding of diseases, build trust and improve outcomes through collaboration. Lavinia is fluent in Spanish and particularly enjoys communicating with her Latin patient population in South Florida as she has a lifelong interest in learning different dialects and connecting with people of various ethnic backgrounds. In her free time, Lavinia particularly enjoys exploring new destinations, she has taste for adventures, unique art galleries and museums, loves cooking and entertaining and she is intentional about pursuing a holistic lifestyle through conscientious choices for a mindful integration of mind, body and soul.

MASLD/MASH Learning Center

Latest News & Blogs

Histological disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

September 2025

CONCLUSIONS: Patients with MASLD, MASL, and MASH, exhibit disease progression. Hypertension and baseline abnormal liver injury test results are predictors of clinical disease progression in patients with MASLD.

Read More arrow

Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) involving hepatocyte destruction, inflammation, and typically pericellular fibrosis, potentially progressing to cirrhosis. Resmetirom, a T3 analogue and an oral agonist of thyroid hormone receptor-β(THR-β), represents a significant advancement in targeted drug therapy for MASH as the first US Food and Drug Administration (FDA)-approved treatment....

Read More arrow

Analysis of miRNA Expression Profiles in High Cholesterol Diet-Induced MASH Progression: Potential Effect of alpha-Tocopherol

September 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD), defined by fat accumulation in more than 5% of hepatocytes, is a common metabolic syndrome worldwide. However, 30%-40% of MAFLD cases progress to metabolic dysfunction-associated steatohepatitis (MASH), increasing the importance of the disease. MicroRNAs (miRNAs), non-coding RNA molecules approximately 21 nucleotides long, are used as biomarkers in many diseases and play a crucial role in regulating cellular processes by affecting...

Read More arrow

Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH

September 2025

CONCLUSION: NITs may be used for assessing a treatment response in patients with MASH. Further studies should confirm the treatment effect of NITs and evaluate the association of NIT changes to outcomes.

Read More arrow

Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review

September 2025

CONCLUSIONS AND RELEVANCE: The prevalence of MASLD and MASH among Hispanic/Latino persons in the US is a significant public health challenge. Addressing this issue requires multifaceted, culturally mindful strategies that target disparities in nutrition, physical activity, genetics, research, and social determinants of health. Clinicians should incorporate routine FIB-4 risk stratification for MASLD in Hispanic/Latino patients with cardiometabolic risk factors to enable early detection and...

Read More arrow

Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver condition lacking approved treatments, where the gut-liver axis is a key therapeutic target. This study aimed to identify novel probiotic strains and elucidate their strain-specific mechanisms by profiling their functional metabolites. We first investigated gut microbiota alterations in a human cohort (n = 151) and then evaluated six selected lactic acid bacteria strains in a Western diet-induced murine...

Read More arrow

Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes

September 2025

CONCLUSION: Treatment with tirzepatide and, to a lesser extent, semaglutide, in patients with T2D, was associated with a lower incidence of MALO compared with DPP4i after 2 years; largely driven by a reduction in the rates of compensated and decompensated cirrhosis. A reduction in MALO was not demonstrated with the use of liraglutide. These findings highlight a comparative benefit of tirzepatide (and semaglutide) versus DPP4i and should prompt more robust, longer-term randomised controlled...

Read More arrow

Proteomic signatures reflect effects of semaglutide treatment for MASH

September 2025

CONCLUSIONS: These findings suggest that SomaSignal MASH component testing may be useful for evaluating the potential therapeutic effects of semaglutide in patients with MASH and related comorbidities. However, prospective randomized clinical trials are necessary to confirm these results.

Read More arrow

GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH

September 2025

CONCLUSIONS: This study demonstrates for the first time the beneficial effects of GTX-11 on portal hypertension and liver fibrosis in MASH by means of HSCs deactivation and endothelial phenotype restoration. Validation in human liver tissues encourages its clinical evaluation as a possible new treatment for this disease.

Read More arrow

Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide. The increase in the prevalence of MASLD is linked to the global rise in obesity. MASLD encompasses a disease spectrum beginning with simple steatosis that may progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocarcinoma. Clinical studies highlight the bidirectional relationship between MASLD and systemic arterial hypertension (SAH), showing...

Read More arrow

Steatotic Liver Diseases (SLDs): A Review

September 2025

Liver steatosis is now the politically correct term for excessive fat in the liver (fatty liver). Its incidence and prevalence, in lockstep with diabetes and obesity, continue to climb to over 2 billion persons worldwide. It is the most common cause of chronic liver disease and the leading cause of liver-related morbidity and mortality. This treatise, resulting from a selection of PubMed literature of relevant steatosis studies since the nomenclature change in 2023, will include the change in...

Read More arrow

BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity

September 2025

Contemporary lifestyle modifications such as changes in nutritional and sleep/wake rhythms increase the risk of metabolic and inflammatory complications linked to obesity, including type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH). BMAL2 (Brain and Muscle ARNT Like Protein 2) is a transcription factor belonging to the circadian clock transcriptional feedback loop which synchronizes internal biological rhythms to environment. In humans, reduced expression in white...

Read More arrow

Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH

September 2025

CONCLUSION: TA3's ability to ameliorate MASH may be associated with the binding of S100A8, which attenuates NETosis and neutrophil infiltration, and inhibits the activation of the TLR4/NF-κB pathway and ROS production.

Read More arrow

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants

September 2025

ALG-055009 is an oral thyroid hormone receptor beta (THR-β) agonist being evaluated for treating metabolic dysfunction-associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG-055009 and bioavailability/food effect. Part 1 was a single-ascending dose study in healthy participants randomized to ALG-055009 (0.1 to 4.0 mg) or placebo. Part 2 was a multiple-ascending dose study in participants with mild hyperlipidemia randomized...

Read More arrow

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH), formally known as nonalcoholic steatohepatitis (NASH), a progressive subtype of nonalcoholic fatty liver disease (NAFLD), remains a major global contributor to liver-related morbidity and mortality. In early 2024, a new therapeutic option, Resmetirom, a liver-directed thyroid hormone receptor beta (THR-β) agonist, became available in the United States for individuals with MASH having moderate to advanced liver fibrosis (F2-F3), offering a...

Read More arrow

Adjustable Intragastric Balloon for Metabolic Dysfunction-associated Steatotic Liver Disease-Enhanced Weight Loss and Histological Improvement

September 2025

CONCLUSION: aIGB effectively induces significant weight loss and improves metabolic and histological parameters in MASLD/MASH patients, with upward volume adjustments enhancing outcomes. The procedure demonstrated an excellent safety profile.

Read More arrow

Association of Kidney Stone Disease With Metabolic Dysfunction Associated Liver Disease and Metabolic Dysfunction Associated Steatohepatitis: A National Inpatient Sample Study

September 2025

CONCLUSION: Patients with SLD were found to have a higher prevalence of KSD. The more pronounced association in MASLD and the lower-than-expected contribution of other conditions involving dysregulation of metabolic homeostasis such as gout or diabetes highlights the central role of SLD in KSD pathogenesis.

Read More arrow

Glycogen Synthase Kinase 3 beta Hepatocyte Deletion Attenuates Ferroptosis and Metabolic Dysfunction-Associated Steatohepatitis in Mice

September 2025

CONCLUSION: Gsk3β^(△Hep) reduced liver injury, mitochondrial DNA release, inflammation, and fibrosis in mice with MASH, secondary to improved mitochondrial bioenergetics and reduced ferroptosis. Therefore, GSK3β may be a potential therapeutic target for human MASH.

Read More arrow

Gut microbiota: A key player for soluble dietary fiber in regulating inflammatory disease

September 2025

Soluble dietary fiber (SDF) plays a significant role in modulating immune responses, particularly in the context of inflammatory diseases. SDF enhances intestinal barrier integrity and regulates immune function by modulating the composition of the gut microbiota and increasing the production of beneficial microbial metabolites, such as short-chain fatty acids (SCFAs), 3-hydroxyoctadecaenoic acid, pentadecanoic acid, and bile acids. Current evidence suggests that SDF holds therapeutic potential...

Read More arrow

Mertk(+) Liver Sinusoidal Endothelial Cells Negatively Regulate PINK1 Related Mitophagy and Accelerate MASH

September 2025

CONCLUSION: Mertk negatively regulates PINK1-mediated mitophagy in LSECs through the p-ERK signaling pathway, thereby accelerating MASH progression. Therefore, LSECs deficient of Mertk should be a novel therapy for reversing PINK1-related mitophagy and MASH.

Read More arrow